Pub Date : 2018-12-01DOI: 10.1016/j.pvr.2018.10.006
Tumelo R. Sekee , Felicity J. Burt , Dominique Goedhals , Jacqueline Goedhals , Yuri Munsamy , Riaz Y. Seedat
Background
Most tumours of the head and neck are attributable to smoking and alcohol use, but an increasing proportion of head and neck tumours are caused by human papillomaviruses (HPVs). The aim of this study was to use in house molecular assays to detect and genotype HPV in biopsies from patients with histologically confirmed head and neck squamous cell carcinomas. In addition, the results were compared with p16 immunohistochemistry staining, which has been described as a potential marker for HPV infection.
Methods
Biopsies of squamous cell carcinomas of the oropharynx, nasopharynx, larynx and hypopharynx from 112 South African patients were screened using three PCR assays targeting the L1 and E6 regions of HPV and p16 immunohistochemical staining.
Results and conclusion
HPV was identified in 7 (6.3%) tumours, while 22 (19.6%) had positive p16 immunohistochemical staining. There was concordance between the results obtained using the three PCR assays. There was substantial agreement between the results of molecular tests and p16 immunohistochemistry for hypopharyngeal carcinomas, but only fair agreement for laryngeal and oropharyngeal carcinomas.
{"title":"Human papillomavirus in head and neck squamous cell carcinomas in a South African cohort","authors":"Tumelo R. Sekee , Felicity J. Burt , Dominique Goedhals , Jacqueline Goedhals , Yuri Munsamy , Riaz Y. Seedat","doi":"10.1016/j.pvr.2018.10.006","DOIUrl":"10.1016/j.pvr.2018.10.006","url":null,"abstract":"<div><h3>Background</h3><p>Most tumours of the head and neck are attributable to smoking and alcohol use, but an increasing proportion of head and neck tumours are caused by human papillomaviruses (HPVs). The aim of this study was to use in house molecular assays to detect and genotype HPV in biopsies from patients with histologically confirmed head and neck squamous cell carcinomas. In addition, the results were compared with p16 immunohistochemistry staining, which has been described as a potential marker for HPV infection.</p></div><div><h3>Methods</h3><p>Biopsies of squamous cell carcinomas of the oropharynx, nasopharynx, larynx and hypopharynx from 112 South African patients were screened using three PCR assays targeting the L1 and E6 regions of HPV and p16 immunohistochemical staining.</p></div><div><h3>Results and conclusion</h3><p>HPV was identified in 7 (6.3%) tumours, while 22 (19.6%) had positive p16 immunohistochemical staining. There was concordance between the results obtained using the three PCR assays. There was substantial agreement between the results of molecular tests and p16 immunohistochemistry for hypopharyngeal carcinomas, but only fair agreement for laryngeal and oropharyngeal carcinomas.</p></div>","PeriodicalId":46835,"journal":{"name":"Papillomavirus Research","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pvr.2018.10.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36691146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-01DOI: 10.1016/j.pvr.2018.10.004
Katherine E. Gallagher , Helen Kelly , Naomi Cocks , Sandra Dixon , Sandra Mounier-Jack , Natasha Howard , Deborah Watson-Jones
Background
The World Health Organization (WHO) recommends a 2-dose HPV vaccine schedule for girls aged 9–14 years. As randomised controlled trials assessing the immunogenicity and efficacy of a 1-dose schedule are ongoing, we interviewed immunisation programme managers and advisors in low and middle-income countries (LMIC) about a hypothetical, future reduction in the HPV vaccine schedule.
Methods
We conducted semi-structured interviews with LMIC immunisation programme managers and national immunisation technical advisory group members (key informants; KIs) in 2017, recruited for their knowledge/experience in national HPV vaccine policy and provision. Data were analysed thematically.
Results
We conducted 30 interviews with KIs from 18 countries. Perceived advantages of a 1-dose schedule included reduced logistical and financial resources needed for vaccine delivery, fewer cold chain requirements and easier integration into routine immunisation services. Perceived challenges included health worker hesitancy, resources needed to re-mobilise communities and re-train health workers, potential misrepresentation of schedule changes by anti-vaccine groups or the media. Half of interviewees suggested a WHO recommendation would be necessary prior to policy change.
Conclusions
We found wide-ranging support among LMIC immunisation managers and advisors for a 1-dose vaccine schedule if research demonstrated immunological and clinical evidence of efficacy, and WHO provided a formal recommendation.
{"title":"Vaccine programme stakeholder perspectives on a hypothetical single-dose human papillomavirus (HPV) vaccine schedule in low and middle-income countries","authors":"Katherine E. Gallagher , Helen Kelly , Naomi Cocks , Sandra Dixon , Sandra Mounier-Jack , Natasha Howard , Deborah Watson-Jones","doi":"10.1016/j.pvr.2018.10.004","DOIUrl":"10.1016/j.pvr.2018.10.004","url":null,"abstract":"<div><h3>Background</h3><p>The World Health Organization (WHO) recommends a 2-dose HPV vaccine schedule for girls aged 9–14 years. As randomised controlled trials assessing the immunogenicity and efficacy of a 1-dose schedule are ongoing, we interviewed immunisation programme managers and advisors in low and middle-income countries (LMIC) about a hypothetical, future reduction in the HPV vaccine schedule.</p></div><div><h3>Methods</h3><p>We conducted semi-structured interviews with LMIC immunisation programme managers and national immunisation technical advisory group members (key informants; KIs) in 2017, recruited for their knowledge/experience in national HPV vaccine policy and provision. Data were analysed thematically.</p></div><div><h3>Results</h3><p>We conducted 30 interviews with KIs from 18 countries. Perceived advantages of a 1-dose schedule included reduced logistical and financial resources needed for vaccine delivery, fewer cold chain requirements and easier integration into routine immunisation services. Perceived challenges included health worker hesitancy, resources needed to re-mobilise communities and re-train health workers, potential misrepresentation of schedule changes by anti-vaccine groups or the media. Half of interviewees suggested a WHO recommendation would be necessary prior to policy change.</p></div><div><h3>Conclusions</h3><p>We found wide-ranging support among LMIC immunisation managers and advisors for a 1-dose vaccine schedule if research demonstrated immunological and clinical evidence of efficacy, and WHO provided a formal recommendation.</p></div>","PeriodicalId":46835,"journal":{"name":"Papillomavirus Research","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pvr.2018.10.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36609927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-06-01DOI: 10.1016/j.pvr.2018.01.001
Aaron Ermel , Marcia L. Shew , Teresa M. Imburgia , Matt Brown , Brahim Qadadri , Yan Tong , Darron R. Brown
Purpose
To assess whether HPV 16 originally detected in adolescent women can be redetected in adulthood.
Methods
A convenience sample of 27 adult women with known HPV 16 detection during adolescence was assessed for HPV 16 redetection. A comparison of the long control region (LCR) DNA sequences was performed on some of the original and redetected HPV 16 isolates.
Results
Median age at reenrollment was 27.5 years (interquartile range of 26.7–29.6). Reenrollment occurred six years on average after the original HPV 16 detection. Eleven of 27 women had HPV 16 redetected. Some of these HPV 16 infections had apparently cleared during adolescence. LCR sequencing was successful in paired isolates from 6 women; in 5 of 6 cases the redetected HPV 16 isolates were identical to those detected during adolescence,
Conclusions
HPV 16 may be episodically detected in young women, even over long time periods. HPV 16 redetection with identical LCR sequences suggests low-level persistent infection rather than true clearance, although newly acquired infection with an identical HPV 16 isolate cannot be excluded. However, this study suggests that a new HPV 16-positive test in a clinical setting may not indicate a new infection.
{"title":"Redetection of human papillomavirus type 16 infections of the cervix in mid-adult life","authors":"Aaron Ermel , Marcia L. Shew , Teresa M. Imburgia , Matt Brown , Brahim Qadadri , Yan Tong , Darron R. Brown","doi":"10.1016/j.pvr.2018.01.001","DOIUrl":"10.1016/j.pvr.2018.01.001","url":null,"abstract":"<div><h3>Purpose</h3><p>To assess whether HPV 16 originally detected in adolescent women can be redetected in adulthood.</p></div><div><h3>Methods</h3><p>A convenience sample of 27 adult women with known HPV 16 detection during adolescence was assessed for HPV 16 redetection. A comparison of the long control region (LCR) DNA sequences was performed on some of the original and redetected HPV 16 isolates.</p></div><div><h3>Results</h3><p>Median age at reenrollment was 27.5 years (interquartile range of 26.7–29.6). Reenrollment occurred six years on average after the original HPV 16 detection. Eleven of 27 women had HPV 16 redetected. Some of these HPV 16 infections had apparently cleared during adolescence. LCR sequencing was successful in paired isolates from 6 women; in 5 of 6 cases the redetected HPV 16 isolates were identical to those detected during adolescence,</p></div><div><h3>Conclusions</h3><p>HPV 16 may be episodically detected in young women, even over long time periods. HPV 16 redetection with identical LCR sequences suggests low-level persistent infection rather than true clearance, although newly acquired infection with an identical HPV 16 isolate cannot be excluded. However, this study suggests that a new HPV 16-positive test in a clinical setting may not indicate a new infection.</p></div>","PeriodicalId":46835,"journal":{"name":"Papillomavirus Research","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pvr.2018.01.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35756217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
As a new initiative, HPV self-sampling to non-attenders using the dry Evalyn self-sampling brush is offered in the Capital Region of Denmark. The use of a dry brush is largely uncharted territory in terms of analytical stability. In this study we aim to provide evidence on the analytical quality of dry HPV self-sampling brushes as a function of time and temperature.
We assessed the analytical stability of dry stored Evalyn brushes at three different temperatures, (4 °C, room temperature, 30 °C) and five different storage time points; T = 0 (baseline), 2, 4, 8, 16, and 32 weeks prior to HPV analysis using the BD Onclarity HPV assay.
Mean Ct value of the Onclarity internal control was used as comparator of cellularity across time and temperatures, with no or only borderline statistical differences observed. HPV detection was stable throughout the five time points. In addition, analytically amplifiable DNA copy numbers and DNA fragmentation was assessed using the Agena iPLEX Exome QC assay, with no or only borderline statistical differences observed.
In conclusion, the Evalyn brush is analytically stable with respect to human genomic material and HPV detection for up to 32 weeks at temperatures ranging from 4 °C to 30 °C.
{"title":"Time and temperature dependent analytical stability of dry-collected Evalyn HPV self-sampling brush for cervical cancer screening","authors":"Ditte Møller Ejegod, Helle Pedersen, Garazi Peña Alzua, Camilla Pedersen, Jesper Bonde","doi":"10.1016/j.pvr.2018.04.005","DOIUrl":"10.1016/j.pvr.2018.04.005","url":null,"abstract":"<div><p>As a new initiative, HPV self-sampling to non-attenders using the dry Evalyn self-sampling brush is offered in the Capital Region of Denmark. The use of a dry brush is largely uncharted territory in terms of analytical stability. In this study we aim to provide evidence on the analytical quality of dry HPV self-sampling brushes as a function of time and temperature.</p><p>We assessed the analytical stability of dry stored Evalyn brushes at three different temperatures, (4 °C, room temperature, 30 °C) and five different storage time points; T = 0 (baseline), 2, 4, 8, 16, and 32 weeks prior to HPV analysis using the BD Onclarity HPV assay.</p><p>Mean Ct value of the Onclarity internal control was used as comparator of cellularity across time and temperatures, with no or only borderline statistical differences observed. HPV detection was stable throughout the five time points. In addition, analytically amplifiable DNA copy numbers and DNA fragmentation was assessed using the Agena iPLEX Exome QC assay, with no or only borderline statistical differences observed.</p><p>In conclusion, the Evalyn brush is analytically stable with respect to human genomic material and HPV detection for up to 32 weeks at temperatures ranging from 4 °C to 30 °C.</p></div>","PeriodicalId":46835,"journal":{"name":"Papillomavirus Research","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pvr.2018.04.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36037464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-06-01DOI: 10.1016/j.pvr.2017.12.003
Anna-Lise Williamson, Suzanne Garland, Joel Palefsky, Ed Rybicki , Margaret Stanley, Silvia de Sanjosé
{"title":"The Cape Town declaration on human papillomavirus related disease","authors":"Anna-Lise Williamson, Suzanne Garland, Joel Palefsky, Ed Rybicki , Margaret Stanley, Silvia de Sanjosé","doi":"10.1016/j.pvr.2017.12.003","DOIUrl":"10.1016/j.pvr.2017.12.003","url":null,"abstract":"","PeriodicalId":46835,"journal":{"name":"Papillomavirus Research","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pvr.2017.12.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35702452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-06-01DOI: 10.1016/j.pvr.2018.03.003
Ana Patricia Ortiz , Daisy González , José Vivaldi-Oliver , Maira Castañeda , Vivian Rivera , Elba Díaz , Hilmaris Centeno , Cristina Muñoz , Joel Palefsky , Kaumudi Joshipura , Cynthia M. Pérez
Introduction
Research on the association between periodontitis and oral human papilloma virus (HPV) infection is inconsistent. The cross-sectional association of severe periodontitis with oral HPV infection was investigated in a sample of Hispanic adults.
Methods
Data from the 2014–2016 San Juan Overweight Adults Longitudinal Study (n = 740) was analyzed. Periodontitis assessment and self-collection of oral HPV samples followed the National Health and Nutrition Examination Survey methodology. Periodontitis was defined using the Centers of Disease Control and Prevention/American Academy of Periodontology definition. HPV typing was performed using polymerase chain reaction. Multivariate logistic regression models were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs).
Results
5.7% of participants had oral HPV infection and 20.3% had severe periodontitis. Adults with severe periodontitis had higher odds of oral HPV infection than those with none/mild disease (OR=2.9, 95% CI: 1.0–8.4, p < 0.05) in multivariable analysis. Adults with clinical attachment loss≥ 7 mm and pocket depth PD≥ 6 mm had 2- to 3-fold higher odds of HPV infection.
Conclusions
Severe periodontitis was positively associated to oral HPV infection. Longitudinal evaluation of periodontal inflammation's role in acquisition and persistence of oral HPV infection is needed, as periodontitis screening could identify individuals at increased risk of HPV-related oral malignancies.
{"title":"Periodontitis and oral human papillomavirus infection among Hispanic adults","authors":"Ana Patricia Ortiz , Daisy González , José Vivaldi-Oliver , Maira Castañeda , Vivian Rivera , Elba Díaz , Hilmaris Centeno , Cristina Muñoz , Joel Palefsky , Kaumudi Joshipura , Cynthia M. Pérez","doi":"10.1016/j.pvr.2018.03.003","DOIUrl":"10.1016/j.pvr.2018.03.003","url":null,"abstract":"<div><h3>Introduction</h3><p>Research on the association between periodontitis and oral human papilloma virus (HPV) infection is inconsistent. The cross-sectional association of severe periodontitis with oral HPV infection was investigated in a sample of Hispanic adults.</p></div><div><h3>Methods</h3><p>Data from the 2014–2016 San Juan Overweight Adults Longitudinal Study (n = 740) was analyzed. Periodontitis assessment and self-collection of oral HPV samples followed the National Health and Nutrition Examination Survey methodology. Periodontitis was defined using the Centers of Disease Control and Prevention/American Academy of Periodontology definition. HPV typing was performed using polymerase chain reaction. Multivariate logistic regression models were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs).</p></div><div><h3>Results</h3><p>5.7% of participants had oral HPV infection and 20.3% had severe periodontitis. Adults with severe periodontitis had higher odds of oral HPV infection than those with none/mild disease (OR=2.9, 95% CI: 1.0–8.4, p < 0.05) in multivariable analysis. Adults with clinical attachment loss≥ 7 mm and pocket depth PD≥ 6 mm had 2- to 3-fold higher odds of HPV infection.</p></div><div><h3>Conclusions</h3><p>Severe periodontitis was positively associated to oral HPV infection. Longitudinal evaluation of periodontal inflammation's role in acquisition and persistence of oral HPV infection is needed, as periodontitis screening could identify individuals at increased risk of HPV-related oral malignancies.</p></div>","PeriodicalId":46835,"journal":{"name":"Papillomavirus Research","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pvr.2018.03.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35927961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-06-01DOI: 10.1016/j.pvr.2018.04.006
Racheal S. Dube Mandishora , Kristina S. Gjøtterud , Sonja Lagström , Babill Stray-Pedersen , Kerina Duri , Nyasha Chin'ombe , Mari Nygård , Irene Kraus Christiansen , Ole Herman Ambur , Mike Z. Chirenje , Trine B. Rounge
Human papillomaviruses (HPVs) co-evolve slowly with the human host and each HPV genotype displays epithelial tropisms. We assessed the evolution of intra HPV genotype variants within samples, and their association to anogenital site, cervical cytology and HIV status. Variability in the L1 gene of 35 HPV genotypes was characterized phylogenetically using maximum likelihood, and portrayed by phenotype. Up to a thousand unique variants were identified within individual samples. In-depth analyses of the most prevalent genotypes, HPV16, HPV18 and HPV52, revealed that the high diversity was dominated by a few abundant variants. This suggests high intra-host mutation rates. Clades of HPV16, HPV18 and HPV52 were associated to anatomical site and HIV co-infection. Particularly, we observed that one HPV16 clade was specific to vaginal cells and one HPV52 clade was specific to anal cells. One major HPV52 clade, present in several samples, was strongly associated with cervical neoplasia. Overall, our data suggest that tissue tropism and HIV immunosuppression are strong shapers of HPV evolution.
{"title":"Intra-host sequence variability in human papillomavirus","authors":"Racheal S. Dube Mandishora , Kristina S. Gjøtterud , Sonja Lagström , Babill Stray-Pedersen , Kerina Duri , Nyasha Chin'ombe , Mari Nygård , Irene Kraus Christiansen , Ole Herman Ambur , Mike Z. Chirenje , Trine B. Rounge","doi":"10.1016/j.pvr.2018.04.006","DOIUrl":"10.1016/j.pvr.2018.04.006","url":null,"abstract":"<div><p>Human papillomaviruses (HPVs) co-evolve slowly with the human host and each HPV genotype displays epithelial tropisms. We assessed the evolution of <em>intra</em> HPV genotype variants within samples, and their association to anogenital site, cervical cytology and HIV status. Variability in the <em>L1</em> gene of 35 HPV genotypes was characterized phylogenetically using maximum likelihood, and portrayed by phenotype. Up to a thousand unique variants were identified within individual samples. In-depth analyses of the most prevalent genotypes, HPV16, HPV18 and HPV52, revealed that the high diversity was dominated by a few abundant variants. This suggests high intra-host mutation rates. Clades of HPV16, HPV18 and HPV52 were associated to anatomical site and HIV co-infection. Particularly, we observed that one HPV16 clade was specific to vaginal cells and one HPV52 clade was specific to anal cells. One major HPV52 clade, present in several samples, was strongly associated with cervical neoplasia. Overall, our data suggest that tissue tropism and HIV immunosuppression are strong shapers of HPV evolution.</p></div>","PeriodicalId":46835,"journal":{"name":"Papillomavirus Research","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pvr.2018.04.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36067311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-06-01DOI: 10.1016/j.pvr.2018.07.016
Jason Kauffman, Naomi Jay, Teresa Darragh, Joel Palefsky, J. Michael Berry-Lawhorn
Background
Office-based or surgical ablation of HSIL may prevent anal cancer; however, limited data exist on long-term outcome regarding HSIL or cancer. It is not established that treating HSIL reduces the incidence of cancer, but long-term remission of HSIL may be a good clinical indicator necessary for cancer prevention.
Methods
Between 2006 and 2008, 369 new patients were diagnosed with HSIL. Follow-up data were extracted in 285/369 patients with HSIL (follow-up not determined in 84). 133 (46.7%) were followed for more than 5 years. As a preliminary analysis, every third patient was analyzed for outcome defined as no HSIL for at least 2 years (HSIL-free) (n=50).
Results
Forty-six patients were men (39 HIV-positive) and 4 were women (1 HIV-positive) ranging in age from 26 to 67 years (mean 45.7 years) and followed from 5.1 to 11.4 years (mean 8.8 years). Patients had between 1–10 (mean 2.58, median 2) ablations to become HSIL-free. Three patients never became HSIL-free; 1 with inadequate follow up and treatment developed cancer at 5.1 years. There was no recurrence of HSIL in 31 patients (62%) followed for 3.2 to 10.1 years (mean 7.0 years). HSIL recurred in 16 patients (32%) at 2.1 to 6.2 years (mean 3.8 years) and only four had another recurrence after becoming HSIL-free.
Conclusions
In patients with more than five years follow-up, 94% became HSIL-free with treatment. Although HSIL recurred in 16 patients, most became HSIL-free. Only 1 patient developed cancer as a result of inadequate treatment. Becoming HSIL-free after ablation may effectively prevent anal cancer.
{"title":"Long term outcome of treatment of high grade squamous intraepithelial lesions (HSIL) in patients with five years follow up","authors":"Jason Kauffman, Naomi Jay, Teresa Darragh, Joel Palefsky, J. Michael Berry-Lawhorn","doi":"10.1016/j.pvr.2018.07.016","DOIUrl":"10.1016/j.pvr.2018.07.016","url":null,"abstract":"<div><h3>Background</h3><p>Office-based or surgical ablation of HSIL may prevent anal cancer; however, limited data exist on long-term outcome regarding HSIL or cancer. It is not established that treating HSIL reduces the incidence of cancer, but long-term remission of HSIL may be a good clinical indicator necessary for cancer prevention.</p></div><div><h3>Methods</h3><p>Between 2006 and 2008, 369 new patients were diagnosed with HSIL. Follow-up data were extracted in 285/369 patients with HSIL (follow-up not determined in 84). 133 (46.7%) were followed for more than 5 years. As a preliminary analysis, every third patient was analyzed for outcome defined as no HSIL for at least 2 years (HSIL-free) (n=50).</p></div><div><h3>Results</h3><p>Forty-six patients were men (39 HIV-positive) and 4 were women (1 HIV-positive) ranging in age from 26 to 67 years (mean 45.7 years) and followed from 5.1 to 11.4 years (mean 8.8 years). Patients had between 1–10 (mean 2.58, median 2) ablations to become HSIL-free. Three patients never became HSIL-free; 1 with inadequate follow up and treatment developed cancer at 5.1 years. There was no recurrence of HSIL in 31 patients (62%) followed for 3.2 to 10.1 years (mean 7.0 years). HSIL recurred in 16 patients (32%) at 2.1 to 6.2 years (mean 3.8 years) and only four had another recurrence after becoming HSIL-free.</p></div><div><h3>Conclusions</h3><p>In patients with more than five years follow-up, 94% became HSIL-free with treatment. Although HSIL recurred in 16 patients, most became HSIL-free. Only 1 patient developed cancer as a result of inadequate treatment. Becoming HSIL-free after ablation may effectively prevent anal cancer.</p></div>","PeriodicalId":46835,"journal":{"name":"Papillomavirus Research","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pvr.2018.07.016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46581281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-06-01DOI: 10.1016/j.pvr.2018.03.006
A.P. Ortiz , G. Tortolero-Luna , J. Romaguera , C.M. Pérez , D. González , C. Muñoz , L. González , E. Marrero , E. Suárez , J.M. Palefsky , G. Panicker , E.R. Unger
Background
To understand risk factors for HPV exposure in Puerto Rican women, we evaluated HPV 6, 11, 16, and 18 serology in women aged living in the San Juan metropolitan area.
Methods
As part of a cross-sectional study, a population-based sample of 524 HPV unvaccinated Hispanic women ages 16–64 years completed face-to-face and computer assisted interviews and provided blood and self-collected anal and cervical specimens. Serology used multiplex virus-like particle based-IgG ELISA and HPV DNA was detected with L1-consensus PCR.
Results
32% and 47% were seropositive to HPV types included in the bivalent (16/18) and quadrivalent (6/11/16/18) vaccines, respectively. Type-specific seroprevalence was HPV6 − 29%, HPV11 − 18%, HPV16 − 23%, and HPV18 − 17%; seroprevalence was high in the youngest age-group (16–19: 26–37%). HPV seropositivity was associated with having ≥ 3 lifetime sexual partners (OR=2.5, 95% CI=1.7–3.9) and detection of anogenital HPV DNA (OR=1.8, 95% CI=1.2–2.6).
Conclusions
The high cumulative exposure of HPV vaccine types 6/11/16/18 in this Hispanic population was influenced by factors related to HPV exposure through sexual behavior. High seroprevalence in the youngest age-group indicates early age of exposure to HPV in Puerto Rico, highlighting the need for HPV vaccination starting prior to age 16.
{"title":"Seroprevalence of HPV 6, 11, 16 and 18 and correlates of exposure in unvaccinated women aged 16–64 years in Puerto Rico","authors":"A.P. Ortiz , G. Tortolero-Luna , J. Romaguera , C.M. Pérez , D. González , C. Muñoz , L. González , E. Marrero , E. Suárez , J.M. Palefsky , G. Panicker , E.R. Unger","doi":"10.1016/j.pvr.2018.03.006","DOIUrl":"10.1016/j.pvr.2018.03.006","url":null,"abstract":"<div><h3>Background</h3><p>To understand risk factors for HPV exposure in Puerto Rican women, we evaluated HPV 6, 11, 16, and 18 serology in women aged living in the San Juan metropolitan area.</p></div><div><h3>Methods</h3><p>As part of a cross-sectional study, a population-based sample of 524 HPV unvaccinated Hispanic women ages 16–64 years completed face-to-face and computer assisted interviews and provided blood and self-collected anal and cervical specimens. Serology used multiplex virus-like particle based-IgG ELISA and HPV DNA was detected with L1-consensus PCR.</p></div><div><h3>Results</h3><p>32% and 47% were seropositive to HPV types included in the bivalent (16/18) and quadrivalent (6/11/16/18) vaccines, respectively. Type-specific seroprevalence was HPV6 − 29%, HPV11 − 18%, HPV16 − 23%, and HPV18 − 17%; seroprevalence was high in the youngest age-group (16–19: 26–37%). HPV seropositivity was associated with having ≥ 3 lifetime sexual partners (OR=2.5, 95% CI=1.7–3.9) and detection of anogenital HPV DNA (OR=1.8, 95% CI=1.2–2.6).</p></div><div><h3>Conclusions</h3><p>The high cumulative exposure of HPV vaccine types 6/11/16/18 in this Hispanic population was influenced by factors related to HPV exposure through sexual behavior. High seroprevalence in the youngest age-group indicates early age of exposure to HPV in Puerto Rico, highlighting the need for HPV vaccination starting prior to age 16.</p></div>","PeriodicalId":46835,"journal":{"name":"Papillomavirus Research","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pvr.2018.03.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35927964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}